Free Trial

Pine Valley Investments Ltd Liability Co Has $5.58 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals logo with Medical background

Pine Valley Investments Ltd Liability Co increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 19.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,303 shares of the biopharmaceutical company's stock after acquiring an additional 848 shares during the quarter. Pine Valley Investments Ltd Liability Co's holdings in Regeneron Pharmaceuticals were worth $5,575,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. State Street Corp increased its holdings in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock worth $707,759,000 after buying an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Regeneron Pharmaceuticals by 12.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock valued at $567,864,000 after buying an additional 59,769 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in shares of Regeneron Pharmaceuticals by 23.8% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock valued at $525,804,000 after buying an additional 96,266 shares during the period. Institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Oppenheimer dropped their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Barclays dropped their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Bank of America reissued an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Finally, Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,099.90.

Check Out Our Latest Report on REGN

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $32.03 on Thursday, hitting $740.97. The company had a trading volume of 924,012 shares, compared to its average volume of 555,532. The stock has a market cap of $81.43 billion, a price-to-earnings ratio of 19.13, a P/E/G ratio of 3.00 and a beta of 0.08. The stock has a 50 day moving average price of $860.87 and a 200 day moving average price of $1,007.41. Regeneron Pharmaceuticals, Inc. has a 1-year low of $735.95 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Should you invest $1,000 in Regeneron Pharmaceuticals right now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Future of Healthcare: 3 AI Stocks Leading the Way
Analysts Predict Big Gains for These 3 Cybersecurity Leaders
This Investment Strategy Has the Highest Payout Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines